Novartis' Anti-Seizure Drug New Target Of PL Suit

Law360, New York (December 5, 2007, 12:00 AM EST) -- Already besieged by hundreds of product liability suits surrounding its contentious bone density drugs, Novartis Pharmaceuticals Corp. is now facing a fresh assault over anti-seizure medication Trileptal.

The lawsuit, believed to be one of the first of its kind, was removed to a Florida district court Monday. It claims Trileptal has life-threatening side effects that Novartis deliberately concealed from consumers.

Plaintiff Lori Feldman initially brought the suit in a Florida state court, alleging she suffered a serious adverse reaction and was diagnosed with the debilitating Stevens-Johnson...
To view the full article, register now.